Literature DB >> 25700368

The long journey of TCL1 transgenic mice: lessons learned in the last 15 years.

Yuri Pekarsky1, Alessandra Drusco, Prasanthi Kumchala, Carlo M Croce, Nicola Zanesi.   

Abstract

The first transgenic mouse of the TCL1 oncogene was described more than 15 years ago, and since then, the overexpression of the gene in T- and B-cells in vivo has been extensively studied to reveal the molecular details in the pathogenesis of some lymphocytic leukemias. This review discusses the main features of the original TCL1 models and the different lines of research successively developed with particular attention to genetically compound mice and the therapeutic applications in drug development.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25700368      PMCID： PMC4963004          DOI： 10.3727/105221615X14181438356256

Source DB:  PubMed          Journal:  Gene Expr        ISSN： 1052-2166


  53 in total

1.  Tcl1 protein functions as an inhibitor of de novo DNA methylation in B-cell chronic lymphocytic leukemia (CLL).

Authors:  Alexey Palamarchuk; Pearlly S Yan; Nicola Zanesi; Linan Wang; Benjamin Rodrigues; Mark Murphy; Veronica Balatti; Arianna Bottoni; Natalya Nazaryan; Hansjuerg Alder; Laura Rassenti; Thomas J Kipps; Michael Freitas; Carlo M Croce; Yuri Pekarsky
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-30       Impact factor: 11.205

2.  Silencing of the inhibitor of DNA binding protein 4 (ID4) contributes to the pathogenesis of mouse and human CLL.

Authors:  Shih-Shih Chen; Rainer Claus; David M Lucas; Lianbo Yu; Jiang Qian; Amy S Ruppert; Derek A West; Katie E Williams; Amy J Johnson; Fred Sablitzky; Christoph Plass; John C Byrd
Journal:  Blood       Date:  2010-11-22       Impact factor: 22.113

3.  In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells.

Authors:  Bradley T Messmer; Davorka Messmer; Steven L Allen; Jonathan E Kolitz; Prasad Kudalkar; Denise Cesar; Elizabeth J Murphy; Prasad Koduru; Manlio Ferrarini; Simona Zupo; Giovanna Cutrona; Rajendra N Damle; Tarun Wasil; Kanti R Rai; Marc K Hellerstein; Nicholas Chiorazzi
Journal:  J Clin Invest       Date:  2005-03       Impact factor: 14.808

4.  Bruton's tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL).

Authors:  Jennifer A Woyach; Engin Bojnik; Amy S Ruppert; Matthew R Stefanovski; Virginia M Goettl; Kelly A Smucker; Lisa L Smith; Jason A Dubovsky; William H Towns; Jessica MacMurray; Bonnie K Harrington; Melanie E Davis; Stefania Gobessi; Luca Laurenti; Betty Y Chang; Joseph J Buggy; Dimitar G Efremov; John C Byrd; Amy J Johnson
Journal:  Blood       Date:  2013-12-05       Impact factor: 22.113

5.  Characterization of the TCL-1 transgenic mouse as a preclinical drug development tool for human chronic lymphocytic leukemia.

Authors:  Amy J Johnson; David M Lucas; Natarajan Muthusamy; Lisa L Smith; Ryan B Edwards; Michael D De Lay; Carlo M Croce; Michael R Grever; John C Byrd
Journal:  Blood       Date:  2006-05-02       Impact factor: 22.113

6.  Overexpression of TCL1 activates the endoplasmic reticulum stress response: a novel mechanism of leukemic progression in mice.

Authors:  Crystina L Kriss; Javier A Pinilla-Ibarz; Adam W Mailloux; John J Powers; Chih-Hang Anthony Tang; Chang Won Kang; Nicola Zanesi; Pearlie K Epling-Burnette; Eduardo M Sotomayor; Carlo M Croce; Juan R Del Valle; Chih-Chi Andrew Hu
Journal:  Blood       Date:  2012-06-12       Impact factor: 22.113

7.  Dysregulation of Frizzled 6 is a critical component of B-cell leukemogenesis in a mouse model of chronic lymphocytic leukemia.

Authors:  Qing-Li Wu; Claudia Zierold; Erik A Ranheim
Journal:  Blood       Date:  2009-01-28       Impact factor: 22.113

Review 8.  Caught up in a Wnt storm: Wnt signaling in cancer.

Authors:  Rachel H Giles; Johan H van Es; Hans Clevers
Journal:  Biochim Biophys Acta       Date:  2003-06-05

9.  Chronic lymphocytic leukemia of Emu-TCL1 transgenic mice undergoes rapid cell turnover that can be offset by extrinsic CD257 to accelerate disease progression.

Authors:  Thomas Enzler; Arnon P Kater; Weizhou Zhang; George F Widhopf; Han-Yu Chuang; Jason Lee; Esther Avery; Carlo M Croce; Michael Karin; Thomas J Kipps
Journal:  Blood       Date:  2009-09-15       Impact factor: 22.113

10.  Mouse models in the study of chronic lymphocytic leukemia pathogenesis and therapy.

Authors:  Giorgia Simonetti; Maria Teresa Sabrina Bertilaccio; Paolo Ghia; Ulf Klein
Journal:  Blood       Date:  2014-07-08       Impact factor: 22.113
View more
  6 in total

1.  Integrated Cellular and Plasma Proteomics of Contrasting B-cell Cancers Reveals Common, Unique and Systemic Signatures.

Authors:  Harvey E Johnston; Matthew J Carter; Kerry L Cox; Melanie Dunscombe; Antigoni Manousopoulou; Paul A Townsend; Spiros D Garbis; Mark S Cragg
Journal:  Mol Cell Proteomics       Date:  2017-01-04       Impact factor: 5.911

2.  B-cell tumor development in Tet2-deficient mice.

Authors:  Enguerran Mouly; Hussein Ghamlouch; Veronique Della-Valle; Laurianne Scourzic; Cyril Quivoron; Damien Roos-Weil; Patrycja Pawlikowska; Véronique Saada; M'Boyba K Diop; Cécile K Lopez; Michaela Fontenay; Philippe Dessen; Ivo P Touw; Thomas Mercher; Said Aoufouchi; Olivier A Bernard
Journal:  Blood Adv       Date:  2018-03-27

Review 3.  Understanding CLL biology through mouse models of human genetics.

Authors:  Elisa Ten Hacken; Catherine J Wu
Journal:  Blood       Date:  2021-12-23       Impact factor: 25.476

Review 4.  Asparaginase treatment side-effects may be due to genes with homopolymeric Asn codons (Review-Hypothesis).

Authors:  Julian Banerji
Journal:  Int J Mol Med       Date:  2015-07-15       Impact factor: 4.101

5.  Analysis of ROR1 Protein Expression in Mice with Reconstituted Human Immune System Components.

Authors:  Carol S Leung
Journal:  J Immunol Res       Date:  2018-04-18       Impact factor: 4.818

6.  The miR-200c/141-ZEB2-TGFβ axis is aberrant in human T-cell prolymphocytic leukemia.

Authors:  Stefan J Erkeland; Christiaan J Stavast; Joyce Schilperoord-Vermeulen; Giada Dal Collo; Harmen J G Van de Werken; Leticia G Leon; Antoinette Van Hoven-Beijen; Iris Van Zuijen; Yvonne M Mueller; Eric M Bindels; Dick De Ridder; Mies C Kappers-Klunne; Kirsten Van Lom; Vincent H J Van der Velden; Anton W Langerak
Journal:  Haematologica       Date:  2022-01-01       Impact factor: 11.047
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.